This report provides an overview of how MMV has been supporting African manufacturers to produce quality-assured antimalarial therapies.
News and resources search
Community Health Workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries
MMV at a glance is an introductory brochure sharing MMV's mission and highlighting our unique partnership model, the growth of our portfolio and the increasing impact of our access work.
A report from Zero Malaria Britain outlining how malaria threatens global health security and Britain's role in eradicating the disease.
Concerns that artemisinin combination treatments are losing their effectiveness against Plasmodium parasites have set scientists looking for alternatives.
Using Cryopreserved Plasmodium falciparum Sporozoites in a Humanized Mouse Model to Study Early Malaria Infection Processes and Test Prophylactic Treatments
Development and application of a PBPK modeling strategy to support antimalarial drug development
Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase
Moving seasonal malaria chemoprevention out of its geographical isolation
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial
Rectal artesunate for severe malaria, implementation research, Zambia
Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
Integration and application of new approach methodologies in assessing the developmental hazards: Case study with an antimalarial drug
Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X
Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline
Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana
The impact of community delivery of intermittent preventive treatment of malaria in pregnancy on its coverage in four sub-Saharan African countries (Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria)
Facilitators and barriers to seasonal malaria chemoprevention (SMC) uptake in Nigeria: a qualitative approach
PDPs remain the chief developers of innovative medical technologies for people suffering with diseases and health threats underserved by traditional markets.